RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this study is to test an experimental drug called RMC-6236. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA). RMC-6236 is currently being investigated in other ongoing studies, and this is the first study investigating RMC-6236 in only pancreatic cancer. You will be randomly assigned to receive either RMC-6236 or a chemotherapy regimen chosen by the study doctor (in the form of combinations of approved drugs 5-fluorouracil, leucovorin, oxaliplatin, irinotecan, and liposomal irinotecan or gemcitabine and nab-paclitaxel). The study will test the effect of RMC-6236 or chemotherapy chosen by the study doctor on your cancer.

Are you Eligible? (Inclusion Criteria)

• At least 18 years of age and has signed consent form 2. Able to take oral medications and willing to keep daily adherence record. 3. Confirmed PDAC with metastatic disease